Interim – Communicable Diseases Research

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Article

Published on 2022-10-062022-11-15
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, 진단,

Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years – United States, July 2022

18세 이상인 사람의 Novavax COVID-19 백신 사용에 대한 예방접종 관행에 대한 자문 위원회의 임시 권고 - 미국, 2022년 7월

Article

Published on 2022-08-052022-09-11
Journal: Morbidity and Mortality Weekly Report [Category] SARS, 변종,

[키워드] 95% CI Administered Adults Alpha variant assessments association authorization B.1.1.7 causal relationship cause Chain Reaction circulating Committee COVID-19 COVID-19 vaccine dose drug Efficacy efficacy analysis Emergency Emergency use authorization EUA FDA flexibility food Food and Drug Administration immunization infection with SARS-CoV-2 information Interim Matrix-M myocarditis Novavax NVX-CoV2373 per-protocol Pericarditis Person polymerase chain reaction Practice predominant PROTECT Protein provide reported reverse transcription Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 symptomatic symptomatic COVID-19 United States vaccination Vaccine vaccine efficacy variant virus
[DOI] 10.15585/mmwr.mm7131a2 PMC 바로가기 [Article Type] Article

Improved HPLC method for the determination of ribavirin concentration in red blood cells and its application in patients with COVID-19

적혈구 내 리바비린 농도 측정을 위한 개선된 HPLC 방법 및 COVID-19 환자에 대한 적용

Article

Published on 2022-07-012022-09-11
Journal: Biomedical chromatography : BMC [Category] 치료제,

Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial

건강한 어린이에서 비활성화된 COVID-19 백신 WIBP-CorV의 안전성 및 면역원성: 무작위, 이중 맹검, 대조, 1/2상 시험의 중간 분석

Clinical Trial

Published on 2022-06-242022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술,

[키워드] adverse events Adverse reaction Adverse reactions age alum Antibody Response assigned children China clinical trial Cohort cohorts conducted Controlled COVID-19 COVID-19 vaccine detectable dose dose-escalation double-blind effective vaccine Effective vaccines elicited Escalation Fever followed by geometric mean geometric mean titer geometric mean titers grade 3 groups healthy children Humoral response immunogenicity inactivated Inactivated vaccine injection injection site pain Interim Intramuscular injection Mild neutralizing antibody participant phase Phase 1 phase 1 trial Phase 2 phase 2 trial Placebo placebo-controlled Randomized Randomly ranged Registered robust Safe Safety safety profile SARS-CoV-2 significantly higher tested three group three groups vaccination Vaccine
[DOI] 10.3389/fimmu.2022.898151 PMC 바로가기 [Article Type] Clinical Trial

Investigation of the use of a sensor bracelet for the presymptomatic detection of changes in physiological parameters related to COVID-19: an interim analysis of a prospective cohort study (COVI-GAPP)

COVID-19와 관련된 생리적 매개변수의 변화를 무증상으로 감지하기 위한 센서 팔찌의 사용 조사: 전향적 코호트 연구(COVI-GAPP)의 중간 분석

Randomized Controlled Trial

Published on 2022-06-212022-09-11
Journal: BMJ Open [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술,

[키워드] age Algorithm Analysis baseline changes in cohort study COVID-19 diagnosed FIVE health & health informatics heart rate HRV Incubation infection control Interim interim analysis investigated investigation memory molecular National parameter participant Participants physiological Physiology positive presymptomatic prospective cohort study Public public health random randomised recall Recurrent Neural Network registration number respiratory rate Safety SARS-COV-2 infection selected sensitivity serological assays setting Short-Term Memory significant changes in symptom onset symptomatic temperature training set Trial Variability Virology were recorded
[DOI] 10.1136/bmjopen-2021-058274 PMC 바로가기 [Article Type] Randomized Controlled Trial

Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)

Research article

Published on 2022-06-012022-10-05
Journal: The Lancet Regional Health - Americas [Category] 임상, 치료법,

[키워드] 95%CI acute lung injury allergic Analysis Antibody titer assigned Bayesian Bayesian framework benefit clinical benefits Clinical improvement clinical trial Combination conducted Controlled clinical trial convalescent plasma COVID-19 COVID-19 progression death Efficacy and safety eligible enrolled evaluate experimental group finding funding hospital hospitalized patient hospitals Innovation intention-to-treat population Interim interquartile range intravenous mean difference median titer Mild multicenter neutralizing antibody no evidence of Open-label Patient performed Plasma transfusion positive RT-PCR Prevent Primary outcome randomization Randomized randomized trial Randomly receive Registered SARS-CoV-2 SARS-CoV2 Science Severe case severe COVID-19 severe COVID-19 patient SOC Standard of care stratified Supportive treatment symptom onset technology the WHO Treatment Volume
[DOI] 10.1016/j.lana.2022.100216 [Article Type] Research article

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial

건강한 일본 성인을 대상으로 한 NVX-CoV2373(TAK-019) 백신의 안전성 및 면역원성: I/II상 무작위 대조 시험 중간 보고

Clinical Trial

Published on 2022-05-262022-09-12
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

[키워드] 95% confidence interval Adults adverse event AEs age AMED anti-SARS-CoV-2 immune response antibody ARMS company conducted COVID-19 Data analysis demonstrated development dose enrolled evaluated Follow-up geometric healthy IgG immune response immunogenicity injection injection site pain Interim Japan Japanese Japanese adults Limited NVX-CoV2373 occurred outcome participant Participants pharmaceutical Placebo placebo-controlled trial Protein Randomized Randomized controlled trial receive reported robust Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nanoparticle vaccine SARS-CoV-2 vaccine screened second dose seroconversion rate serum IgG stratified subject Takeda vaccination Vaccine
[DOI] 10.1016/j.vaccine.2022.04.035 PMC 바로가기 [Article Type] Clinical Trial

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

6~11세 어린이의 mRNA-1273 Covid-19 백신 평가

Clinical Trial

Published on 2022-05-112022-09-25
Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료법,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered Adults age Analysis assigned authority B.1.617.2 children circulating coronavirus coronavirus disease criterion development dominant dose effective Efficacy Estimated events fatigue groups headache immune response incidence Infection Inflammatory injection Injection-site pain Interim interquartile range median mRNA-1273 mRNA-1273 vaccine myocarditis Neutralizing antibody titer observer-blinded open label Part participant phase 2–3 trial phase 3 trial Placebo placebo-controlled Prevent public health Randomly receive reported response Result Safe Secondary objective selected Serious Adverse Events Serologic response Symptoms syndrome the vaccine transient adverse Trial Vaccine variant was selected Year
[DOI] 10.1056/NEJMoa2203315 PMC 바로가기 [Article Type] Clinical Trial

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

COVID-19(TICO)로 입원한 성인을 위한 두 가지 중화 단일클론항체 치료제인 소트로비맙과 BRII-196과 BRII-198의 효능 및 안전성: 무작위 대조 시험

Randomized Controlled Trial

Published on 2022-05-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단,

[키워드] addition adjusted adjusted odds ratio Administered analyses Analysis assigned Biotechnology Clinical outcome clinical recovery clinical trial Complication complications of COVID-19 COVID-19 COVID-19 symptom death defined Denmark died discharge double-blind Efficacy Efficacy and safety eligible enrolled enrolment female hospital hospitalised Inpatient Interim intravenously laboratory-confirmed SARS-CoV-2 infection male matching placebo median age modified intention-to-treat monoclonal antibody neutralising operation Organ failure outcome participant Patient Placebo placebo group placebo-controlled Poland Primary outcome randomisation randomised randomised controlled trial Randomly recruited Registered Serious Adverse Events significantly higher single dose speed Standard of care stratified study drug sustained Switzerland the placebo group Therapeutics Therapies therapy Treatment Trial USA were assessed with COVID-19
[DOI] 10.1016/S1473-3099(21)00751-9 PMC 바로가기 [Article Type] Randomized Controlled Trial

Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry

COSA(Seraph® 100 Microbind® Affinity 필터로 치료한 코로나19 환자) 레지스트리의 중간 분석

Article

Published on 2022-03-252022-09-11
Journal: Nephrology, dialysis, transplantation : official p [Category] SARS, 치료법,

[키워드] 30-day mortality rate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse events adverse outcome adverse outcomes affinity Analysis assessment authorization average bacterial superinfection Blood Characteristics clinical Complete coronavirus coronavirus disease Coronavirus disease 2019 correlated country COVID COVID-19 COVID-19 patient COVID-19 patients Cox regression demonstrated Device died drug Efficacy Emergency Emergency use authorization evaluate event extracorporeal treatment failure failure rate FDA ferritin ferritin levels Filter Follow-up food Food and Drug Administration hospital ICU ICU admission ICU patient ICU Patients intensive care Interim kidney median Mortality mortality rate multivariate multivariate Cox regression non-ICU non-ICU patients nucleocapsid outcome parameter Pathogens Patient patients patients treated performed predicted Premature reduction registry removal replacement therapy reported representing SARS-CoV-2 SARS-CoV-2 virus Seraph severe acute respiratory syndrome Coronavirus severe coronavirus disease shown SOFA SOFA scores Symptoms the SARS-CoV-2 virus therapy treated Treatment treatment for COVID-19 treatment of COVID-19 Viraemia Viral load viruses were excluded while
[DOI] 10.1093/ndt/gfab347 PMC 바로가기 [Article Type] Article